Compare IX & ALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IX | ALC |
|---|---|---|
| Founded | 1950 | 1945 |
| Country | Japan | Switzerland |
| Employees | N/A | N/A |
| Industry | Diversified Financial Services | Ophthalmic Goods |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8B | 39.0B |
| IPO Year | N/A | 2002 |
| Metric | IX | ALC |
|---|---|---|
| Price | $34.07 | $84.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $89.21 |
| AVG Volume (30 Days) | 318.8K | ★ 2.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.13% | 0.25% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.82 | $8.13 |
| Revenue Next Year | $5.97 | $6.62 |
| P/E Ratio | ★ $12.93 | $38.31 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.75 | $71.55 |
| 52 Week High | $37.04 | $99.20 |
| Indicator | IX | ALC |
|---|---|---|
| Relative Strength Index (RSI) | 52.79 | 60.00 |
| Support Level | $29.41 | $84.43 |
| Resistance Level | $37.04 | $89.90 |
| Average True Range (ATR) | 0.61 | 1.68 |
| MACD | -0.21 | 0.58 |
| Stochastic Oscillator | 15.24 | 70.18 |
ORIX Corp is a diversified financial services company with operations in Corporate Financial Services, Maintenance Leasing, Real Estate, PE Investment and Concession, Environment and Energy, Insurance, Banking and Credit, Aircraft and Ships, ORIX USA, ORIX Europe, Asia, and Australia and engages in various other fee businesses by providing products and services aligned with customer needs to its core customer base of domestic small and medium-sized enterprises. Orix's numerous divisions finance leases of large-ticket items like ships, airplanes, and technology equipment. The company generates the majority of its revenue from Corporate Financial Services and Maintenance Leasing operations and Real Estate operations.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.